Clinical trial
A Study Of Poly (ADP-Ribose) Polymerase Inhibitor PF-01367338 In Combination…
NCT01009190 · pharmaand GmbH, Industry · Completed
Key facts
| NCT number | NCT01009190 |
|---|---|
| Title | A Study Of Poly (ADP-Ribose) Polymerase Inhibitor PF-01367338 In Combination With Several Chemotherapeutic Regimens |
| Official title | A Parallel Arms Phase 1 Safety, Pharmacokinetic And Pharmacodynamic Study Of The Intravenous Poly (ADP-Ribose) Polymerase (PARP) Inhibitor PF-01367338 (AG-014699) In Combination With Several Chemotherapeutic Regimens In Adult Patients With Advanced Solid Tumor |
| Lead sponsor | pharmaand GmbH, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Advanced Solid Tumors |
| Intervention type | Drug |
| Interventions | PF-01367338, Carboplatin |
| Enrollment | 85 |
| Start date | Feb 1, 2010 |
| Primary completion | Apr 1, 2014 |
| Completion | Apr 1, 2014 |
| First posted | Nov 6, 2009 |
| Last update posted | Jun 8, 2023 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: